Avenue Therapeutics (NASDAQ:ATXI) and Bio-Path (NASDAQ:BPTH) Head-To-Head Survey

Risk & Volatility

Avenue Therapeutics has a beta of -0.93, meaning that its share price is 193% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500.

Institutional & Insider Ownership

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Avenue Therapeutics and Bio-Path’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Bio-Path	N/A	-2,842.40%	-337.48%

Valuation & Earnings

This table compares Avenue Therapeutics and Bio-Path”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38 million	($0.94)	-0.37
Bio-Path	N/A	N/A	-$16.08 million	($1.06)	-0.05

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Summary

Avenue Therapeutics beats Bio-Path on 7 of the 8 factors compared between the two stocks.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

About Bio-Path

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.